Newamsterdam Pharma Stock Buy Hold or Sell Recommendation
| NAMS Stock | 24.07 0.46 1.95% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding NewAmsterdam Pharma is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell NewAmsterdam Pharma given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for NewAmsterdam Pharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out NewAmsterdam Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide. Note, we conduct extensive research on individual companies such as NewAmsterdam and provide practical buy, sell, or hold advice based on investors' constraints. NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
NewAmsterdam |
Execute NewAmsterdam Pharma Buy or Sell Advice
The NewAmsterdam recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NewAmsterdam Pharma. Macroaxis does not own or have any residual interests in NewAmsterdam Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NewAmsterdam Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
NewAmsterdam Pharma Trading Alerts and Improvement Suggestions
| NewAmsterdam Pharma generated a negative expected return over the last 90 days | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 45.56 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Newamsterdam Pharma COO Kling sells 2.36 million in stock - Investing.com India |
NewAmsterdam Pharma Returns Distribution Density
The distribution of NewAmsterdam Pharma's historical returns is an attempt to chart the uncertainty of NewAmsterdam Pharma's future price movements. The chart of the probability distribution of NewAmsterdam Pharma daily returns describes the distribution of returns around its average expected value. We use NewAmsterdam Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NewAmsterdam Pharma returns is essential to provide solid investment advice for NewAmsterdam Pharma.
| Mean Return | -0.08 |
| Value At Risk | -4.59 |
| Potential Upside | 6.09 |
| Standard Deviation | 3.03 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NewAmsterdam Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
NewAmsterdam Stock Institutional Investors
The NewAmsterdam Pharma's institutional investors refer to entities that pool money to purchase NewAmsterdam Pharma's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | |||
| Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 2.1 M | |
| Alliancebernstein L.p. | 2024-12-31 | 1.9 M | |
| Polar Capital Holdings Plc | 2024-12-31 | 1.8 M | |
| Hhg Plc | 2024-12-31 | 1.7 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 1.2 M | |
| Adage Capital Partners Gp Llc | 2024-12-31 | 1.1 M | |
| Capital World Investors | 2024-12-31 | 1 M | |
| Citadel Advisors Llc | 2024-12-31 | 975.8 K | |
| Timessquare Capital Management, Llc | 2024-12-31 | 895.6 K | |
| Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 10.7 M | |
| Fcpm Iii Services Bv | 2024-12-31 | 10.6 M |
NewAmsterdam Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NewAmsterdam Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NewAmsterdam Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NewAmsterdam stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.11 | |
β | Beta against Dow Jones | -0.34 | |
σ | Overall volatility | 2.99 | |
Ir | Information ratio | -0.0037 |
NewAmsterdam Pharma Volatility Alert
NewAmsterdam Pharma exhibits very low volatility with skewness of 0.96 and kurtosis of 1.86. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure NewAmsterdam Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact NewAmsterdam Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.NewAmsterdam Pharma Fundamentals Vs Peers
Comparing NewAmsterdam Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NewAmsterdam Pharma's direct or indirect competition across all of the common fundamentals between NewAmsterdam Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as NewAmsterdam Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NewAmsterdam Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NewAmsterdam Pharma to competition |
| Fundamentals | NewAmsterdam Pharma | Peer Average |
| Return On Equity | -0.46 | -0.31 |
| Return On Asset | -0.18 | -0.14 |
| Operating Margin | (3.38) % | (5.51) % |
| Current Valuation | 1.77 B | 16.62 B |
| Shares Outstanding | 109.82 M | 571.82 M |
| Shares Owned By Insiders | 0.25 % | 10.09 % |
| Shares Owned By Institutions | 99.33 % | 39.21 % |
| Number Of Shares Shorted | 2.91 M | 4.71 M |
| Price To Book | 3.43 X | 9.51 X |
| Price To Sales | 56.91 X | 11.42 X |
| Revenue | 45.56 M | 9.43 B |
| Gross Profit | 45.56 M | 27.38 B |
| EBITDA | (241.49 M) | 3.9 B |
| Net Income | (241.6 M) | 570.98 M |
| Total Debt | 448 K | 5.32 B |
| Book Value Per Share | 7.01 X | 1.93 K |
| Cash Flow From Operations | (158.56 M) | 971.22 M |
| Short Ratio | 4.40 X | 4.00 X |
| Earnings Per Share | (2.56) X | 3.12 X |
| Target Price | 45.77 | |
| Number Of Employees | 68 | 18.84 K |
| Beta | -0.035 | -0.15 |
| Market Capitalization | 2.59 B | 19.03 B |
| Total Asset | 864.62 M | 29.47 B |
| Retained Earnings | (558.57 M) | 9.33 B |
| Working Capital | 756.5 M | 1.48 B |
| Net Asset | 864.62 M |
Note: Disposition of 100000 shares by Douglas Kling of NewAmsterdam Pharma at 23.16 subject to Rule 16b-3 [view details]
NewAmsterdam Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NewAmsterdam . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About NewAmsterdam Pharma Buy or Sell Advice
When is the right time to buy or sell NewAmsterdam Pharma? Buying financial instruments such as NewAmsterdam Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having NewAmsterdam Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Recreation theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.